Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 9/20 | 0.39 |
| ▸ | MMP1 | P03956 | 6/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470099 | 0.89 | RNPEP (0.37) | CA2CA1MMEACECPA1 | |
| SCHEMBL5471418 | 0.84 | MAPT (0.39) | MMEACECPA1ACE2MMP3 | |
| SCHEMBL29240100 | 0.81 | CA2 (0.60) | CA2CA1MMEACECPA1 | |
| SCHEMBL25090841 | 0.77 | CA2 (0.57) | CA2CA1MAPK1MMP3MMP1 | |
| SCHEMBL29060619 | 0.77 | — | — | |
| SCHEMBL6539560 | 0.76 | CA2 (0.45) | CA2CA1DPP7SLC15A1MAPK1 | |
| SCHEMBL23449935 | 0.76 | CA1 (0.48) | CA2CA1ACE2DPP7SLC15A1 | |
| SCHEMBL10211776 | 0.76 | CA1 (0.48) | CA2CA1ACE2DPP7SLC15A1 | |
| SCHEMBL5456370 | 0.76 | RNPEP (0.48) | MMEACECPA1ACE2 | |
| SCHEMBL7020554 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | NEU1, NEU3, NEU2 | CA2 1616/4885CA1 614/4885MME 112/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | CA2 1616/4885CA1 614/4885MME 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.